This study aimed to compare, using optical coherence tomography (OCT), the outcomes of bioabsorbable drug-eluting stent with those of bare metal stent (BMS) following implantation in porcine iliac artery.
Methods:
After the placement of BMS and bioabsorbable drug-eluting stents, we used OCT and digital subtraction angiography to investigate stent appositions, arterial neointima, evagination, and restenosis at 1 and 3 months.
Results:
At 1 and 3 months after stent implantation, OCT study was performed to investigate 32 stents and 21 788 struts. Thirty-three malapposed struts were found in the bioabsorbable drug-eluting stent groups and 2 were found in BMS groups. The average neointimal thickness, area, and in-stent stenosis were significantly lower in bioabsorbable drug-eluting stents than in BMS, while the frequency of malapposed struts was higher in the bioresorbable drug-eluting stent groups. Average neointimal thickness was lower in bioabsorbable drug-eluting stents than in BMS at 1 (0.19 ± 0.09 vs 0.67 ± 0.75 mm; P < .001) and 3 months (0.21 ± 0.08 vs 1.52 ± 0.28 mm; P < .001).
Conclusion:
Our study suggested that bioabsorbable drug-eluting stent is more effective in decreasing arterial restenosis than BMS in animal models.
FarbABurkeAPKolodgieEDVirmaniR. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation. 2003;108(14):1701–1706.
2.
OngATMcFaddenEPRegarEde JaegerePPvan DomburgRTSerruysPW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45(12):2088–2092.
3.
KinnmanNFrancozCBarbuV. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest. 2003;83(2):163–173.
4.
PatkowskiWNyckowskiPZieniewiczK. Biliary tract complications following liver transplantation. Transplant Proc. 2003;35(6):2316–2317.
5.
BosiersMPeetersPD’ArchambeauO. Ams insight absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Intervent Radiol. 2009;32(3):424–435.
6.
ZartnerPCesnjevarRSingerHWeyandM. First successful implantation of a biodegradable metal stent into the left pulmonary artery of a preterm baby. Catheter Cardiovasc Interv. 2005;66(4):590–594.
7.
SchranzDZartnerPMichel-BehnkeIAkintürkH. Bioabsorbable metal stents for percutaneous treatment of critical recoarctation of the aorta in a newborn. Catheter Cardiovasc Interv. 2006;67(5):671–673.
8.
KainerKU. Semi Solid Injection Molding Of Magnesium Alloys And Their Applications. Munich, Germany: WILEY-VCH Verlag GmbH; 2000;557–658.
9.
MusC. Magnesium die casting, history, principles and state of the art. Magnesium Industry. 2001;2:21–25.
10.
QiangHZhentaoYYafengZ. The deformability of magnesium alloy AZ31 rolling at room temperature. Rare Metal Mat Eng. 2008;37(4):829–831.
11.
WaksmanRPakalaRKuchulakantiPK. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv. 2006;68(4):607–617.
12.
JianxiangCDefengW. Research progress on transesterification of biodegradable polymer blends. Plastics. 2014;43(2):34–37.
13.
ZhouShijieLiuLiLiZhi. Mg-Ca-Mn, Mg-Ca-Sr preparation and study of ternary biomagnesium alloy. Materials Review. 2013;27(20):7–9.
BaoLinGMaPX. Synthetic biodegradable functional polymers for tissue engineering: a brief review. Sci China Chem. 2014;57(4):490–500.
16.
YuxiaZXueLQingM. Research progress of biodegradable blends of poly (D, L-lactic acid)/adipic acid-butylene terephthalate copolymer. China Plastics. 2014;28(3):7–15.
17.
PingwangD. Preparation of degradable polylactic acid porous microspheres. Applied Chemical Industry. 2014;43(3):449–452.
18.
DanielBriePeterPensonMaria-CorinaSerban. Bioresorbable scaffold—A magic bullet for the treatment of coronary artery disease?Int J Cardiol. 2016;215:47–59.
19.
KereiakesDean J.EllisStephen G.ChristopherMetzger. 3-Year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds the ABSORB III trial. J Am Coll Cardiol. 2017;23(70):2583–2862.
FinnAVJonerMNakazawaG. Pathological correlates of late drug-eluting stent thrombosis: stent coverage as a marker of endothelialization. Circulation. 2007;115(18):2435–2441.
22.
AttizzaniGFCapodannoDOhnoYTamburinoC. Mechanisms, pathophysiology, and clinical aspects of incomplete stent apposition. J Am Coll Cardiol. 2014;63(14):1355–1367.
23.
de DonatoGSetacciFSirignanoPGalzeranoGCappelliASetacciC. Optical coherence tomography after carotid stenting: rate of stent malapposition, plaque prolapse and fibrous cap rupture according to stent design. Eur J Vasc Endovasc Surg. 2013;45(6):579–587.
24.
OzakiYOkumuraMIsmailTF. The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study. Eur Heart J. 2010;31(12):1470–1476.
25.
ParodiGLa MannaADi VitoL. Stent-related defects in patients presenting with stent thrombosis: differences at optical coherence tomography between subacute and late/very late thrombosis in the mechanism of stent thrombosis (MOST) study. EuroIntervention. 2013;9(8):936–944.
26.
BrenerSJPrasadAJKhanZSacchiTJ. The relationship between late lumen loss and restenosis among various drug-eluting stents: a systematic review and meta-regression analysis of randomized clinical trials. Atherosclerosis. 2011;214(1):158–162.
27.
SiqueiraDAAbizaidAACosta JdeR. Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. Eur Heart J. 2007;28(11):1304–1309.
28.
CookSLadichENakazawaG. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009;120(5):391–399.
29.
XingxuePXianW. Progress in the study of thrombosis process and mechanism. Medical Recapitulate. 2011;17(11):1613–1616.
30.
JonerMFinnAVFarbA. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193–202.
31.
JohnMCWesselyRKastratiA. Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. JACC Cardiovasc Interv. 2008;1(5):535–544.
32.
VirmaniRGuagliumiGFarbA. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?Circulation. 2004;109(6):701–705.
33.
NakazawaGFinnAVVorpahlMLadichERKolodgieFDVirmaniR. Coronary responses and differential mechanisms of late stent thrombosis attributed to first generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol. 2011;57(4):390–398.
34.
OrhøjTKTuSLassenJFDijkstraJChristiansenEHHolmNR. Acquired peri-stent evaginations in a second generation durable polymer drug eluting stent. Cardiovasc Revasc Med. 2013;14(4):246–247.
35.
CollinsT.Role of IVUS, OCT and FFR in peripheral vascular intervention. JICC J Indian Coll Cardiol. 2017;7(3):123–125.
36.
KaiSWeiZYingSWenqiuP. Primary observation of optical coherence tomography after head and neck endovascular stenting. Intervent Radiol. 2016;25(9):766–770.
